Stage I Multiple Myeloma Treatment

• Status: Unknown status
• Trial end date: 2012-11-01
• Target enrollment: 0
• Participant gender: All

Summary

• Assessment of survival without progression of stage I MM in two groups: arm A: simple survey and arm B: administration of Zoledronate.

• Describe different progression's type noticed and define the prognosis factors of a fast evolution.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Centre Hospitalier Universitaire de Nice
• Treatments: Zoledronic Acid

Criteria

Inclusion Criteria:

• stage I multiple myeloma without bones injuries

Exclusion Criteria:

• abnormal kidney function

• VIH infection

• Hepatic incapacity

• pregnancy

• Associate pathology